Pharmaceutical industry embraces cyclic peptides as FDA fast-tracks Merck candidate

Summary

This article from the Eye on Patents column discusses the pharmaceutical industry's growing interest in cyclic peptides as drug candidates. It highlights Merck & Co.'s cyclic peptide enlicitide decanoate, which was selected by the FDA for a new pilot program (Commissioner's National Priority Voucher) that aims to review important drug candidates in just 1-2 months instead of the typical 6+ months. The piece explores how these circular molecules are gaining traction in drug development.

Source

bskyPharmaceutical industry embraces cyclic peptides as FDA fast-tracks Merck candidatecen.acs.org